TRIP13

Across TCGA pan-cancer cohorts, TRIP13 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRIP13 data layer compared with 30 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher TRIP13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRIP13 expression acts as an unfavorable survival marker.

OV, BLCA, and LUAD are the cancer types where TRIP13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.308	0.691	.033	18	view →
BLCA	DFS	Median	All	0.114	0.626	<.001	12	view →
LUAD	OS	Median	II,III,IV	0.174	0.712	<.001	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LGG	OS	Median	All	0.350	0.799	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRIP13–OV (OS)

Open the OV breakdown →